​Nobel Laureate Professor Gregg L. Semenza visited aCGT, focusing on the new development of the cell industry

On December 4, 2023, Professor Gregg L. Semenza, 2019 Nobel Laureate in Physiology or Medicine, Double Fellow of the National Academy of Medicine, and Professor of the Department of Genetic Medicine at Johns Hopkins University School of Medicine, visited Asia Cell Therapeutics (Zhejiang) Co., Ltd. (aCGT) . Qi Nianmin, Chairman of aCGT, introduced the company's overall scientific research progress and discussed possible directions and some details of cooperation.


 △ Professor Semenza and Chairman Professor Qi Nianmin and others took a group photo at aCGT

Nobel laureate Professor Greg Semenza Visited aCGT

The aCGT's GMP Base is located in Pudong, Shanghai, covering an area of nearly 8000 square meters, with over 4000 square meters of GMP clean space for stem cell production. It is a leading domestic platform for cell research and production.



 △ aCGT GMP base

With the introduction of Professor Qi Nianmin's team, firstly, Professor Greg Semenza came to the company exhibition hall to learn about the development process of aCGT. Since its establishment in 2016, aCGT has been deeply involved in the field of cell drug research and development, committed to promoting high-quality clinical research of stem cell products, as well as innovative cell storage and preparation technologies. It relies on cell technology for health management, disease treatment, and always takes safeguarding national health as its ultimate goal. Professor Semenza highly affirmed the development of spring living organisms and hoped for further in-depth understanding


Subsequently, at the technical exchange meeting, Professor Qi Nianmin's team introduced the company's current scientific research progress, clinical achievements, and future development plans. As of now, aCGT has submitted a total of 6 PreINDs to the CENTER FOR DRUG EVALUATION, NMPA (CDE), of which 4 have received IND acceptance numbers from the CDE (CXSL2200301, CXSL2200299, CXSL2200341, CXSL2200457). This marks that the company's research and development level of innovative cell drugs is in a leading position in China.


In the aCGT's GMP base, the technical team introduced the development of the company's scientific research projects to Professor Semenza in detail. Professor Semenza expressed his high appreciation for aCGT 's achievements in cell technology innovation and cell product research and development. The technical team had in-depth exchanges and discussions with Professor Semenza on current technological breakthroughs, core technology optimization, and further upgrading of cell products.






At the end, Professor Qi Nianmin's team welcomed the arrival of Professor Semenza again, saying: "I am very happy to meet Professor Semenza, and aCGT will continue to promote the research and development of innovative biological drugs. Through this visit, we hope to enhance mutual exchanges, promote cooperation and jointly promote the vigorous development of domestic innovative biological drugs. ”


Concentrate on the courage to practice innovation level

Prof. Semenza attended the Anji CGT Symposium

On December 3, Professor Greg Semenza was invited to attend the "2023 2nd Anji Liangshan International Cell and Gene Therapy (CGT) Industry Innovation Symposium" co-organized by aCGT. He discussed the development of the cell and gene therapy industry with four academicians of the Chinese Academy of Sciences, including Pei Gang, Yang Shengli, Li Jinsong and Zhang Dan, as well as 150 clinical experts and representatives of leading enterprises and investment institutions.

aCGT is committed to regenerative medicine research

Promote transformation for the benefit of the people

aCGT is a high-tech enterprise mainly focusing on cell storage, cell drug research and development, and preparation technology innovation. It relies on cell technology for health management, disease treatment, etc., committed to promoting high-quality clinical research of stem cell products, and always with the ultimate goal of safeguarding national health.

The core team has decades of experience in the field of global drug innovation, and has participated in the R&D and commercial production of more than 10 marketed biologics. Join hands with domestic and foreign scientists, including Nobel laureates, to accelerate the research and development of new drugs and promote the development of advanced technologies in the field of regenerative medicine.


In the future, aCGT will continue to play its role as a major scientific research enterprise, contribute high-quality scientific and technological innovation achievements to the society, and create greater social value in clinical application and market promotion.

Gregg L. Semenza

Nobel Prize in Physiology or Medicine

Professor Gregg L. Semenza is     mainly engaged in research in the field of hypoxia inducible factors (HIF) .He     has published more than 400 papers . The cumulative number of cited papers exceeds 100,000     times. He is also a member of the National Academy of Sciences and the     National Academy of Medicine, and a professor in the Department of Genetic     Medicine at the Johns Hopkins University School of Medicine. In 2016, he     received the Lasker Award for Basic Medical Research. Professor Gregg L.     Semenza, along with Professor William Kaelin and Peter Ratcliffe, jointly     won the 2019 Nobel Prize in Physiology or Medicine.